Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

[1]  A. Ferrando,et al.  Metabolic dependencies and vulnerabilities in leukemia , 2019, Genes & development.

[2]  J. Sarry,et al.  Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia , 2019, BMC Biology.

[3]  M. Konopleva,et al.  A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia , 2018, Leukemia & lymphoma.

[4]  F. Ravandi,et al.  A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML) , 2015 .

[5]  E. Jabbour,et al.  Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments , 2015, Drugs & Aging.

[6]  F. Appelbaum,et al.  SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia , 2014, British journal of haematology.

[7]  M. Millenson,et al.  Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines , 2013 .

[8]  Z. Estrov,et al.  Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD , 2013, British journal of haematology.

[9]  M. Levis,et al.  Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. , 2012, Blood.

[10]  E. Estey,et al.  Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. , 2005, Blood.

[11]  F. Appelbaum,et al.  Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. , 2004, Blood.

[12]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Kantarjian,et al.  A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. , 1996, Blood.

[14]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.